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Membrane type 4 matrix metalloproteinase (MT4-MMP) [matrix metallopro-
teinase (MMP) 17] is a GPI-anchored membrane-type MMP expressed on the
cell surface of human breast cancer cells. In triple-negative breast cancer cells,
MT4-MMP promotes primary tumour growth and lung metastases. Although
the trafficking and internalization of the transmembrane membrane type 1
MMP have been extensively investigated, little is known about the regulatory
mechanisms of the GPI-anchored MT4-MMP. Here, we investigated the fate
and cellular trafficking of MT4-MMP by analysing its homophilic complex
interactions, internalization and recycling dynamics as compared with an inert
form, MT4-MMP-E249A. Oligomeric and dimeric complexes were analysed by
cotransfection of cells with FLAG-tagged or Myc-tagged MT4-MMP in reduc-
ing and nonreducing immunoblotting and coimmunoprecipitation experiments.
The trafficking of MT4-MMP was studied with an antibody feeding assay and
confocal microscopy analysis or cell surface protein biotinylation and western
blot analysis. We demonstrate that MT4-MMP forms homophilic complexes at
the cell surface, and internalizes in early endosomes, and that some of the
enzyme is either autodegraded or recycled to the cell surface. Our data indicate
that MT4-MMP is internalized by the clathrin-independent carriers/GPI-
enriched early endosomal compartments pathway, a mechanism that differs
from that responsible for the internalization of other membrane-type MMP
members. Although MT4-MMP localizes with caveolin-1, MT4-MMP internal-
ization was not affected by inhibitors of caveolin-1 or clathrin endocytosis path-
ways, but was reduced by CDC42 or RhoA silencing with small interfering
RNA. We provide a new mechanistic insight into the regulatory mechanisms of
MT4-MMP, which may have implications for the design of novel therapeutic
strategies for metastatic breast cancer.
Abbreviations
CAV-1, caveolin-1; CHC-1, clathrin heavy chain 1; CLIC/GEEC, clathrin-independent carriers/GPI-enriched early endosomal compartments;
DMEM, Dulbecco’s modified Eagle’s medium; EEA1, early endosome antigen 1; FACS, fluorescence-activated cell sorting; IP,
immunoprecipitation; MESNA, 2-mercaptoethane sulfonic acid; MMPI, matrix metalloproteinase inhibitor; MMP, matrix metalloproteinase;
MT1-MMP, membrane type 1 matrix metalloproteinase; MT4-MMP, membrane type 4 matrix metalloproteinase; MT6-MMP, membrane
type 6 matrix metalloproteinase; MT-MMP, membrane-type matrix metalloproteinase; NS, not significant; SBS, Soerensen Buffer; SEM,
standard error of the mean; siRNA, small interfering RNA; TIMP, tissue inhibitor of metalloproteinase; WT, wild-type.
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Introduction
Matrix metalloproteinase (MMP) activity is strictly
regulated in normal tissue, and proteolytic events are
fine-tuned within spatiotemporal windows that main-
tain normal physiological function. In pathological
conditions, uncontrolled MMP activity leads to tissue
damage in numerous diseases, such as rheumatoid
arthritis, scleroderma, aneurism rupture, and cancer
invasion and metastases [1–4]. MMP activity is regu-
lated through various mechanisms, including activation
by prodomain cleavage and inhibition by physiological
inhibitors [tissue inhibitor of MMP (TIMP)] [5–7].
MMP complex formation constitutes another mecha-
nism of MMP regulation. For instance, the activities
of MMP9 [8], MMP2 [9] and membrane type 1 MMP
(MT1-MMP) [10] can be regulated by the formation
of homodimers at the cell surface. The specific local-
ization of some MMPs at the cell membrane allows
the MMPs to contribute to the shedding or cleavage
of cell surface receptors and regulation of intracellular
signalling [11–15]. These membrane-type MMPs (MT-
MMPs) are classified into two subgroups [16–18]: (a)
transmembrane MMPs, which contain a transmem-
brane domain, and include MT1-MMP (MMP14),
membrane type 2 MMP (MMP16), membrane type 3
MMP (MMP15), and membrane type 5 MMP
(MMP24); and (b) GPI-anchored MMPs, including
membrane type 4 MMP (MT4-MMP) (MMP17) and
membrane type 6 MMP (MT6-MMP) (MMP25). In
addition to the ability of MT-MMPs to degrade a
plethora of extracellular substrates, including extracel-
lular matrix components, growth factors, cytokines,
and chemokines [5,19,20], new roles have been
assigned to MT-MMPs as key mediators of leukocyte
function and the immune response [21]. Recent
advances include the appreciation of a nonproteolytic
function of MT-MMPs leading to cell migration, sig-
nalling, and proliferation [22–24].
The availability and stability of MT-MMPs at the
cell surface are tightly regulated by their trafficking,
internalization, and recycling. Although the internal-
ization and trafficking of MT1-MMP, membrane type
2 MMP and membrane type 3 MMP are well docu-
mented, little is known about the fate of the GPI-
anchored MT-MMPs (MT4-MMP and MT6-MMP)
[18]. Homophilic interactions of MT1-MMP are widely
recognized as being crucial for its stability and ability
to activate proMMP2 and exert collagenolytic activity
[25–27]. Such interactions between two MT1-MMP
molecules involve either covalent intermolecular inter-
actions through disulfide bridges of cysteines [28,29] or
noncovalent interactions through the MT1-MMP
hemopexin domain [30,31]. In GPI-anchored MT4-
MMP and MT6-MMP, homophilic interactions have
been reported to involve cysteines in the stem regions
of these molecules. However, the importance of MT4-
MMP homophilic interactions for enzyme internaliza-
tion and stability, and the role of the catalytic function
of MT4-MMP, are unclear. MT4-MMP has recently
emerged as a key driver in breast cancer growth and
metastasis in vivo [32–34]. Proangiogenic and prometa-
static effects of MT4-MMP can be abrogated by an
inactivating mutation (E249A) in the catalytic site of
the enzyme [32]. In addition to its proteolytic activity,
MT4-MMP affects breast cancer cell proliferation by
interacting with epidermal growth factor receptor and
enhancing its activation in response to ligand [24].
Superimposition of MT4-MMP and epidermal growth
factor receptor has been observed in human triple-
negative breast cancer specimens [24]. Our recent data
revealed both proteolytic and nonproteolytic functions
of MT4-MMP, and targeting of these functions to
interfere with different steps in cancer progression (in-
cluding tumour cell proliferation, angiogenesis, cancer
invasion, and metastatic dissemination) is warranted.
In this context, a better understanding of MT4-MMP
fate at the cell surface and intracellular trafficking of
MT4-MMP in cancer cells is essential for the design of
efficient strategies to counteract its protumorigenic and
prometastatic effects [35].
Here, we demonstrate that MT4-MMP forms oligo-
mers and colocalizes with caveolin-1 (CAV-1) at the cell
surface. After MT4-MMP internalization, which occurs
within 45 min, some of the enzyme is intracellularly
autodegraded, whereas the remaining intact MT4-MMP
proteins are recycled to the cell surface. Our study
provides evidence for the involvement of the clathrin-
independent carriers/GPI-enriched early endosomal
compartments (CLIC/GEEC) pathway in MT4-MMP
internalization, highlighting unique features of
MT4-MMP among membrane-associated MMPs.
Results
MT4-MMP is internalized and autodegraded
The internalization dynamics of MT4-MMP were
investigated in MDA-MB-231 cells stably transfected
with: (a) the control vector pcDNA3-neo (control plas-
mid); (b) full-length active human MT4-MMP cDNA
[MT4-wild-type (WT)]; or (c) cDNA of the inert form
of MT4-MMP containing a point mutation (E249A) in
its catalytic domain (MT4-E249A). All MT4-MMP
constructs contained a FLAG tag in the hinge region
(Fig. 1A). MT4-MMP expression in transfected cells
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was analysed by RT-PCR (Fig. 1B) and western blot-
ting under reducing conditions, with antibodies against
FLAG and MT4-MMP (Fig. 1C,D). A cell surface
protein biotinylation assay was performed to analyse
the amount of internalized MT4-MMP at different
time points (Fig. 2A). After biotinylation, cells were
incubated at 37 °C for different times (15, 30, 45 and
60 min), and cell surface biotin was removed with 2-
mercaptoethane sulfonic acid (MESNA). Biotinylated
proteins in the total cell lysates were pulled down with
streptavidin beads, and analysed by western blotting
with an antibody against FLAG. As expected, MT4-
WT and MT4-E249A were found at the cell surface,
and no enzyme was detected after treatment with
MESNA at time 0 (Fig. 2B). MT4-WT and MT4-
E249A were detected in cells 15 min after cell treat-
ment with MESNA and incubation at 37 °C, and the
internalization of MT4-E249A was enhanced after
45–60 min. MT4-WT was less abundant than MT4-























































































































Fig. 1. Generation of MT4-MMP constructs and stably transfected MDA-MB-231 cells. (A) Schematic illustration of MT4-MMP cDNA
constructs. Full-length MT4-MMP contains a signal sequence, a prodomain, a furin cleavage site (RXR/KR), a catalytic domain, a hinge
region, a hemopexin-like domain (‘Hemopexin’), a stem region, and a GPI anchor. A Myc or FLAG tag was inserted into MT4-MMP cDNA
(MT4-WT-FLAG or MT4-WT-Myc) to allow detection by antibody against Myc or FLAG. The replacement of the glutamic acid at position 249
with alanine in the highly conserved domain HExxHxxGxxH generates an inactive enzyme (MT4-E249A). FLAG or Myc was also inserted
into this inert form (MT4-E249A-FLAG or MT4-E249A-Myc). Two substitutions of cysteine with serines were also generated (C564S and
C566S) as single or combined mutations. (B–D) MT4-MMP expression was analysed by RT-PCR (B) and western blotting for MT4-MMP
with antibody against FLAG (C) or MT4-MMP (D) in cell lysates from MDA-MB-231 cells stably transfected with control vector pcDNA3-neo
(CTR plasmid), full-length tagged MT4-MMP (MT4-WT-FLAG), or the inert tagged form (MT4-E249A-FLAG). 28S rRNA and actin were used
as loading controls for RT-PCR and western blot analysis, respectively. IB, immunoblotting.
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suggesting either lack of internalization of the active
form or possible degradation during its internalization.
To assess this possibility, MT4-WT cells were incu-
bated with the broad-spectrum MMP inhibitor
(MMPI) BB94 (20 lM), and subjected to the biotinyla-
tion assay. Interestingly, treatment with BB94
increased the amounts of internalized MT4-WT
detected at the different time points (Fig. 2B). These
data were confirmed with an antibody feeding assay
and confocal microscopy analysis followed by comput-
erized quantification of the internalized MT4-MMP
(see Experimental procedures). In MT4-E249A cells,
internalized MT4-MMP was visible as green spots in
the cytoplasm. In the absence of BB94, only a few
spots were detectable in MT4-WT cells, even after
60 min. In contrast, MT4-MMP degradation was com-
pletely prevented by the MMPI (Fig. 2C). Computer-
ized quantification of internalized MT4-MMP (51–97
cells) after 60 min in the presence or absence of MMPI
(BB94) confirmed the restoration of the active WT
form to a similar level as the inert form (Fig. 2D).
These data demonstrate that MT4-MMP is internal-
ized and partially autodegraded, a process that is pre-
vented by the inactivation of its catalytic domain or
treatment with BB94. Having obtained similar effects
with pharmacological MMP inhibition and mutation-
driven catalytic inactivation, we thereafter compared
the fate of WT and catalytically inert MT4-MMP
forms expressed by stably transfected cells in the
absence of MMPIs.
MT4-MMP is internalized in early endosomes and
recycled to the cell surface
The intracellular trafficking of MT4-MMP was next
investigated with an antibody feeding assay and
immunofluorescent staining of endosomes. MT4-MMP
(marked in green) was found to be associated with
early endosome antigen 1 (EEA1)-positive endosomes
(marked in red) 10 min after the internalization of
MT4-MMP from the cell surface (Fig. 2E). This asso-
ciation was even more pronounced at 30 min and
60 min in both MT4-WT and MT4-E249A cells, as
shown by yellow spots.
The MT4-MMP internalization prompted us to
assess whether recycling of the enzyme that was not
degraded during this process was occurring. For this
purpose, and because of the partial autodegradation of
MT4-MMP during its internalization, we increased the
amount of protein used for the immunoprecipitation
(IP) to 800 lg instead of the 600 lg used in Fig. 2B,
to allow the detection of MT4-WT during its recycling.
Cells were biotinylated and incubated for 45 min at
37 °C to allow the internalization of MT4-MMP, and
treated with MESNA to remove all of the biotinylated
proteins remaining at the cell surface. Then, a second
incubation at 37 °C for 30 min allowed the recycling
of proteins to the cell membrane, and a second treat-
ment with MESNA was performed to cleave all of the
biotinylated MT4-MMP re-exposed at the cell surface
(Fig. 3A). The pulldown of biotinylated proteins in the
total cell lysates and western blotting revealed that
MT4-MMP was recycled to the cell surface by 30 min
after its internalization in both MT4-WT and MT4-
E249A cells (Fig. 3B). The difference between
MESNA-treated and untreated cells at 30 min repre-
sents the amount of protein recycled to the cell sur-
face. Similarly to the data in Fig. 2B, the density of
the total amount of internalized active form (lane 6
versus lane 5) was lower than that of the inert form
(lane 2 versus lane 1). The density ratios of the
recycled active (lane 8 versus lane 6) and inert (lane 4
versus lane 2) forms were similar. These data demon-
strate that intact MT4-MMP is recycled to the cell
surface, and that the inactivation mutation E249A
increased its stability but did not affect its internaliza-
tion and recycling dynamics.
MT4-MMP forms homophilic complexes
To investigate in detail the homophilic complexes
formed by MT4-MMP, we generated single and dou-
ble mutations, i.e. C564S and C566S, in the stem
regions of MT4-WT and MT4-E249A containing a
Myc or FLAG tag inserted into the hinge region
(Fig. 1A). MT4-MMP homophilic complexes were
analysed by western blotting under nonreducing condi-
tions in COS-1 and MDA-MB-231 cells transfected
with MT4-WT and MT4-E249 cDNA (Fig. 4A).
Under nonreducing conditions, MT4-WT and MT4-
E249A were found as monomers (65-kDa species),
dimers (130-kDa species), and many oligomers
(260-kDa species). Next, COS-1 cells were double-
transfected with FLAG-tagged and Myc-tagged MT4-
WT, and this was followed by IP of Myc-tagged pro-
teins and western blotting for the FLAG tag under
reducing conditions (Fig. 4B). MT4-MMP–FLAG was
immunoprecipitated with MT4-MMP–Myc, which
confirmed the formation of homophilic complexes of
the enzyme. To determine whether the binding of
TIMP2 or MMPIs to the catalytic domain of MT4-
MMP could disturb these interactions, COS-1 cells
were double-transfected with MT4-WT and MT4-
E249A containing either a FLAG or Myc tag, and
incubated with BB94, GM6001, or TIMP2; this was
followed by IP for Myc and western blotting for
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FLAG under reducing conditions (Fig. 4C). FLAG-
tagged MT4-WT and MT4-E249A were immunopre-
cipitated with the Myc-tagged enzyme in the absence
or presence of DMSO, BB94, GM6001, or TIMP2.
These results indicated that MT4-MMP oligomeriza-
tion does not require an intact catalytic domain and is
not impaired by the binding of an inhibitor. Intrigu-
ingly, a 130-kDa band of MT4-MMP was detectable
under reducing conditions after the IP experiments;
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Fig. 3. MT4-MMP is recycled to the cell surface. (A) Schematic representation of the recycling assay of MT4-MMP in MT4-WT-expressing
and MT4-E249A-expressing MDA-MB-231 cells. After cell surface biotinylation (black spots), the cells were incubated for 45 min at 37 °C to
allow internalization of cell surface proteins. A first treatment with MESNA removed biotin remaining at the cell surface, and was followed
by a second incubation at 37 °C for 30 min to allow the recycling of biotinylated enzymes. A second MESNA treatment cleaved all of the
biotinylated proteins re-exposed on the surface. Protein extracts were immunoprecipitated with streptavidin beads, and separated by SDS/
PAGE to analyse the expression of MT4-MMP by immunoblotting with an antibody against FLAG. Differences between the conditions with
subjection or not to the second MESNA treatment determine the amount of recycled enzyme at the cell surface. (B) Western blot analysis
of MT4-MMP expression after the recycling assay as described in (A). The difference between lane 3 and 4 or between lane 7 and 8
represents the amount of protein recycled to the cell surface during the second incubation at 37 °C. Densitometry quantification of western
blot band is represented by arbitrary units (a.u.). The density ratio of internalized and recycled MT4-MMP is normalized to lane 1 for MT4-
E249A and to lane 5 for MT4-WT.
Fig. 2. MT4-MMP is internalized in early endosomes and autodegraded. (A) Schematic representation of the internalization assay of MT4-
MMP in MT4-WT-expressing and MT4-E249A-expressing MDA-MB-231 cells. After cell surface biotinylation (black spots), the cells were
incubated at 37 °C for different times to allow internalization of cell surface proteins. Treatment with MESNA removed biotin remaining at
the cell surface. The cells had previously been incubated or not with BB94 (20 lM). (B) Detection of internalized (+ MESNA) or total (
MESNA) biotinylated MT4-MMP-FLAG or MT4-E249A-FLAG at different time points in MDA-MB-231 cells by western blot analysis with an
antibody against FLAG. MT4-MMP-FLAG cells were incubated or not with BB94. (C) Internalization dynamics of MT4-WT and its inert form
MT4-E249A in MDA-MB-231 cells after 0, 30 and 60 min determined by an antibody feeding assay with an Alexa Fluor 488-coupled
antibody against FLAG (green). Cells were incubated or not with BB94 24 h before the assay. (D) Computerized quantification of confocal
images representing internalized MT4-WT and MT4-E249A in MDA-MB-231 cells at 60 min in the presence or absence of BB94. The data
and statistical analysis in (D) are representative of three independent experiments (n = 3) performed in biological triplicates. Data are
presented as the mean ( SEM) of the ratio between the intracellular staining areas and the cell surface (internalized MT4-MMP density).
Wilcoxon–Mann–Whitney tests were performed. NS, P > 0.05; **P ≤ 0.01; ****P ≤ 0.0001. (E) Antibody feeding assay of MT4-MMP
combined with coimmunofluorescence with EEA1 performed in MT4-WT-expressing or MT4-E249A-expressing MDA-MB-231 cells at the
indicated time points. MT4-MMP was labelled with an antibody against FLAG as green spots, and EEA1 was detected as red spots.
Internalized MT4-MMP colocalized with EEA1-positive endocytic markers in MDA-MB-231 cells as shown by yellow spots (white arrows).
The cells were observed under a confocal microscope and using a 60X objective.
709FEBS Journal 283 (2016) 704–722 ª 2015 FEBS
A. Truong et al. Internalization and recycling of MT4-MMP
covalent bonding of two molecules released from the
large oligomeric complexes of MT4-MMP (Fig. 4A).
Similar stable dimers (130 kDa) were also detected,
but to a lesser extent, under reducing conditions,
whereas oligomers were completely dissolved in these
conditions (Figs 1C and 4B). Different antibodies
directed against different epitopes, including antibody
against MT4-MMP or antibody against FLAG, under
reducing conditions confirmed that the 130-kDa band
was specific to MT4-MMP (data not shown). Our data
support the concept that MT4-MMP dimers could be
held by both covalent and noncovalent bonds. The
persistence of MT4-MMP oligomers in the presence of
MMPIs, including BB94, GM6001, and TIMP2, was
confirmed by nonreducing western blotting in MDA-
MB-231 and COS-1 cells, in which MT4-MMP dimers
were still observed at 130 kDa (Fig. 4D).
To test whether MT4-MMP homophilic interactions
are dependent on Cys564 and/or Cys566 residues in its
stem region, COS-1 cells were transfected with MT4-
MMP cDNA bearing either a single mutation (C564S
or C566S) or a double mutation (C564S and C566S)
(Fig. 1A). Under nonreducing conditions, all forms of
MT4-MMP (65-kDa monomers, 130-kDa dimers, and
260-kDa oligomers) were found in cells transfected
with MT4-WT, MT4-E249A, MT4-C564S, and/or
MT4-C566S constructs (Fig. 5A). Similar results were
obtained in double-transfection experiments followed
by IP and western blotting (Fig. 5B). MT4-FLAG-
C564S, MT4-FLAG-C566S and MT4-FLAG-C564S-
C566S were found to be immunoprecipitated with their
respective proteins containing a Myc tag, suggesting
that the homophilic interactions of MT4-MMP were
not inhibited by the cysteine mutations in the stem
region. However, the 130-kDa band of MT4-MMP,
which was still detected under reducing conditions,
was decreased by the C564S mutation but not by the
C566S mutation. Double mutation of the two cysteines
led to the same result as the single C564S mutation,
with no additional inhibitory effects. In agreement
with previous data from Sohail et al. [36], these data
confirm the role of Cys564 in MT4-MMP homophilic
interactions, but also demonstrate a possible role of
other noncovalent interactions that are independent of
the cysteines in the stem region.
To further analyse the effects of C564S and C566S
mutations on MT4-MMP internalization, we com-
pared the internalization of MT4-C564S-C566S with
that of MT4-WT in the biotinylation assay after
45 min (Fig. 5C). Similar levels of the MT4-MMP
proform (65 kDa) were found at the cell surface of
COS-1 cells at time 0 without MESNA. No difference
was observed between the WT form of MT4-MMP
and MT4-WT-C564S-C566S after 45 min of internal-
ization. MT4-MMP in COS-1 cells is mainly produced
as inactive proform (65 kDa) that is endocytosed and
found intact intracellularly, as it is protected from
autodegradation. In agreement with the data in
Fig. 2B, the amount of the active form (57 kDa) was
lower in COS-1 cells, owing to its autodegradation
during its internalization. Collectively, these data indi-
cate that, under the experimental conditions used
here, the C564S and C566S mutations did not affect
MT4-MMP internalization. However, large homophilic
complexes may involve other hydrophobic and polar
interactions through the hemopexin domain of
MT4-MMP.
MT4-MMP internalization involves the CLIC/
GEEC pathway
Like most GPI-anchored proteins, MT4-MMP has
been found in lipid rafts, which constitute a membrane
microdomain enriched in glycosphingolipids and
cholesterols [36]. This observation was confirmed by
immunofluorescence and confocal microscopy analy-
ses, which showed colocalization of MT4-MMP with
CAV-1 at the cell surface (Fig. 6A). Interestingly, both
Fig. 4. MT4-MMP forms dimers and oligomers in the presence or absence of its catalytic activity. (A) Nonreducing western blot analysis of
MT4-WT-FLAG and its inactive form MT4-E249A-FLAG with an antibody against FLAG in MDA-MB-231 cells stably transfected (left panel) or
COS-1 cells transiently transfected (right panel) with MT4-MMP constructs or a control vector (CTR plasmid). (B) Total cell lysates from
COS-1 cells double-transfected with MT4-WT-FLAG and MT4-WT-Myc constructs were immunoprecipitated with an antibody against Myc,
and then blotted with an antibody against FLAG or an antibody against Myc as a loading control. The detection of FLAG after anti-Myc IP
demonstrates the homophilic interaction of MT4-MMP molecules. COS-1 cells transfected with a control vector (control plasmid) or single
MT4-MMP containing either a FLAG or Myc tag were used as controls for the IP. Western blots with FLAG and Myc antibody on total cell
lysates from transfected cells are indicated. (C) Detection of MT4-MMP homophilic complexes in COS-1 cells double-transfected with MT4-
WT-Myc and active or inactive MT4-MMP (MT4-WT-FLAG or MT4-E249A-FLAG, respectively) incubated with MMPIs (GM6001 and BB94)
or TIMP2 or DMSO (used as control) for 24 h. Total cell lysates were subjected to IP with an antibody against Myc and western blotting
with an antibody against FLAG. (D) Nonreducing western blot analysis of MT4-WT-FLAG with an antibody against FLAG in MDA-MB-231
and COS-1 cells transfected with MT4-MMP constructs and incubated for 24 h with control (CTR) (DMSO), MMPIs (GM6001 and BB94), or
TIMP2. IB, immunoblotting.
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MT4-WT and MT4-E249A were found to colocalize
with CAV-1, as shown by yellow spots in MDA-MB-
231 cells (Fig. 6A). In contrast, no association of
MT4-MMP with clathrin was detected in these cells
(Fig. 6B). Despite the fact that MT4-MMP colocalized
with CAV-1, incubating the cells with multiple
concentrations (5 lgmL1 and 10 lgmL1) of filipin
III, a caveolae pathway inhibitor, before the antibody
feeding assay failed to influence MT4-WT or MT4-
E249A internalization (Fig. 6C). Similarly, treatment
with a clathrin inhibitor, chlorpromazine (5 lgmL1),
did not block MT4-MMP internalization (Fig. 6C).
Computerized quantification of the MT4-MMP inter-
nalization density (40–60 cells) did not reveal any
effect of chlorpromazine or filipin III in MT4-WT and
MT4-E249A cells (Fig. 6D). We then hypothesized
that MT4-MMP may utilize the CLIC/GEEC path-
way. This pathway is commonly used for GPI-
anchored protein endocytosis, and is dependent on
Rho GTPases, such as CDC42 and RhoA. We first
silenced CDC42 with small interfering RNA (siRNA),
and performed the antibody feeding assay to track
MT4-MMP internalization. The expression of CDC42
was reduced by 80% in cells transfected with CDC42
siRNA in comparison with control scrambled siRNA
(Fig. 7A). MT4-MMP internalization in CDC42
siRNA and control cells was followed by incubation
with an antibody against FLAG and a cell membrane
tracker (Fig. 7B). This antibody feeding assay revealed
that MT4-MMP green spots initially localized at the
cell surface were found in the cytoplasm within 30 min
in the control cells (scrambled siRNA). In contrast,
only few cytoplasmic spots of MT4-MMP were
observed in CDC42-silenced cells, revealing impaired
MT4-MMP internalization. Quantification analysis of
the antibody feeding assay experiments (74–77 cells)
confirmed a significant reduction in MT4-MMP inter-
nalization by CDC42 siRNA as compared with
scrambled siRNA (Fig. 7C). However, MT4-MMP did
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Fig. 5. Mutation of cysteines in the stem region of MT4-MMP
does not affect its oligomerization. (A) Nonreducing western blot
analysis of MT4-MMP in COS-1 cells transiently transfected with a
control vector (CTR plasmid), MT4-WT-FLAG, MT4-E249A-FLAG, or
MT4-WT containing the C564S and/or C566S mutations and
containing a FLAG or Myc tag insertion. MT4-MMP molecules
containing the single or double mutations C564S and C566S were
detected as monomers, dimers, and oligomers. (B) Total cell
lysates from COS-1 cells transfected with the two MT4-MMP
FLAG and Myc constructs containing the C564S and/or C566S
mutations were immunoprecipitated with an antibody against Myc
and blotted with an antibody against FLAG. Western blotting
against Myc was used as a loading control for the IP. (C) Detection
of internalized (+ MESNA) or total ( MESNA) biotinylated MT4-
WT and its mutated form containing the double mutation C564S
and C566S in COS-1 cells after cell surface biotinylation and
incubation for 45 min at 37 °C. IB, immunoblotting.
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ing, suggesting that the enzyme may have been sub-
jected to degradation and/or shedding. To check this
hypothesis, internalization of the inert form MT4-
E249A was followed with an antibody feeding assay in
cells transfected with scrambled or CDC42 siRNA
(Fig. 7A). Confocal immunofluorescence image and
quantification analysis of the MT4-E249A remaining at
the cell surface (62–85 cells) after 30 min of incubation
confirmed the inhibitory effect of CDC42 siRNA on
MT4-MMP internalization (Fig. 7D,E). After 30 min
of incubation, inactive MT4-E249A was well internal-
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Fig. 6. MT4-MMP endocytosis is not clathrin-dependent or caveolin-dependent. (A, B) Immunofluorescence of MT4-MMP with an antibody
against FLAG (green) and CAV-1 (A) or clathrin (CHC-1) (B) (red) in MDA-MB-231 cells expressing MT4-WT-FLAG or MT4-E249A-FLAG. High
magnification in (A): the dashed area shows colocalization (yellow spots) of MT4-MMP with CAV-1 at the cell surface. (C) Antibody feeding
assay of MT4-WT-FLAG-expressing or MT4-E249A-FLAG-expressing cells with an antibody against FLAG and incubation with a caveolin
inhibitor, filipin III, at 5 lgmL1 and 10 lgmL1 or with a clathrin inhibitor, chlorpromazine, at 5 lgmL1 did not affect the internalization of
MT4-MMP (MT4-WT) or its inactive form (MT4-E249A). The cells were observed under confocal microscope and using a 60X objective. (D)
Computerized quantification of internalized MT4-WT and MT4-E249A in MDA-MB-231 cells at 30 min. Data and statistical analysis are
representative of three independent experiments (n = 3) performed in biological triplicates. Data are presented as the mean ( SEM) of the
ratio between the intracellular staining areas and the cell surface (internalized MT4-MMP density). For statistical analysis, Wilcoxon–Mann–
Whitney tests were performed. NS, P > 0.05. CTR, control.
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cells transfected with scrambled siRNA, whereas the
amount of noninternalized MT4-E249A remained high
and stable at the cell surface in cells transfected with
CDC42 siRNA (P < 0.0001).
We next extended our study to Rac1 and RhoA,
and conducted fluorescence-activated cell sorting
(FACS) analysis to quantify the MT4-MMP available
at the cell surface. Approximately 80% downregula-
tion was achieved with the different siRNAs against
CDC42, Rac1, and RhoA (Fig. 7F). FACS analyses
showed increases in MT4-MMP availability at the cell
surface of ~ 28% for CDC42 siRNA, 33% for RhoA
siRNA and 11% for Rac1 siRNA as compared with
scrambled siRNA (Fig. 7G). Thus, MT4-MMP inter-
nalization is primarily dependent on CDC42 and
RhoA, and to a lesser extent on Rac1, indicating that
MT4-MMP proficiently utilizes the CLIC/GEEC
pathway (rather than caveolin-dependent or clathrin-
dependent pathways) for its internalization.
Discussion
Recent evidence from our team [33] and other groups
[34,37,38] has assigned mitogenic, protumorigenic and
prometastatic functions to MT4-MMP, and these
activities rely on both proteolytic and nonproteolytic
activities [24,32]. Understanding the mechanisms regu-
lating MT4-MMP availability at the cell surface is
important for interfering with this unique multifunc-
tional GPI-bound MMP. Although many studies have
focused on the internalization and recycling of MT1-
MMP, the trafficking of the prometastatic MT4-MMP
has not yet been described. Herein, we demonstrate
that MT4-MMP is internalized and recycled to the cell
surface. By using coimmunoprecipitation experiments,
and nonreducing and reducing western blotting, we
found that MT4-MMP forms dimers and/or oligomers.
These homophilic interactions were not abrogated by
either an inactivating E249A mutation in the catalytic
site or inhibition with synthetic (GM6001 and BB94)
or physiological (TIMP2) MMPIs. These findings
demonstrate that MT4-MMP homophilic interactions
are independent of its catalytic activity.
A previous study by Sohail et al. [36] showed that
the C564S mutation is sufficient to prevent MT4-
MMP dimerization, whereas the C566S mutation has
minimal effects on this process. In contrast, we found
that, under nonreducing SDS/PAGE conditions, the
C564S and C566S mutations do not affect MT4-MMP
dimerization or oligomerization. Large quantities of
MT4-MMP-C564S, MT4-MMP-C566S and MT4-
MMP-C564S-C566S were found in abundant mono-
meric (65 kDa), dimeric (130 kDa) and oligomeric
(260 kDa) species. Nevertheless, the level of a 130-
kDa form, found after IP of MT4-MMP-Myc and
reducing western blotting against FLAG, was
decreased by the C564S mutation. This 130-kDa form
may correspond to MT4-MMP oligomers, whereas the
dimers are detected as 65-kDa species after IP experi-
ments. Similarly, the double mutation of C564S and
C566S in the stem region of MT4-MMP reduced the
formation of this 130-kDa form without completely
inhibiting other homophilic interactions. These con-
flicting data might appear to be inconsistent with pre-
vious evidence of C564S involvement in MT4-MMP
dimerization [36]. However, this inconsistency might
be explained by differences in lipid raft formation and
cell membrane fluidity between the MDCK cells previ-
ously used [36] and the MDA-MB-231 and COS-1
cells used here.
Our data demonstrate that only a fraction of MT4-
MMP molecules contribute to the formation of cova-
lent dimers though intermolecular disulfide bonds and
suggest the existence of other noncovalent interactions.
The DTT-resistant or 2-mercaptoethanol-resistant 130-
kDa band might correspond to a noncovalently
Fig. 7. MT4-MMP is dependent on CLIC/GEEC pathway endocytosis. (A) Western blot analysis of CDC42 in MT4-MMP-expressing MDA-
MB-231 cells incubated with CDC42 or scrambled siRNA (Scr). Actin was used as a loading control. (B) Antibody feeding assay for MT4-WT
(green) after a 30-min incubation at 37 °C. Cell membranes were marked in red with cell tracker. (C) Computerized quantification of confocal
images representing internalized MT4-WT in MDA-MB-231 cells at 30 min. The cells were observed under confocal microscope and using a
60X objective. (D) Antibody feeding assay for MT4-E249A (green) after a 30-min incubation at 37 °C. Cell membranes were marked in red
with cell tracker. (E) Computerized quantification of confocal images representing cell surface MT4-E249A in MDA-MB-231 cells at 30 min.
The data and statistical analysis in (D) and (E) are representative of two independent experiments (n = 2) performed in biological triplicates.
Data are presented as the mean ( SEM), and statistical analyses were performed with Wilcoxon–Mann–Whitney tests. *P ≤ 0.05;
****P ≤ 0.0001. (F) Western blot analysis of CDC42, Rac1 and RhoA in MT4-MMP cells incubated with CDC42, Rac1, RhoA or scrambled
siRNA. Actin was used as a loading control. (G) FACS analysis of MT4-MMP levels at the cell surface (intact cells) after CDC42, Rac1, RhoA
or scrambled siRNA transfection in MDA-MB-231 cells. The median fluorescence intensity (MFI) for each condition was normalized to
control cells (MDA-MB-231 cells expressing empty pcDNA3-neo vector) and compared with the scrambled siRNA, which was considered to
be 100%. FACS data are presented as the mean  standard deviation of three independent experiments (n = 3).
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bonded MT4-MMP dimer held by hydrophobic inter-
actions. The detection of this band by three different
antibodies excluded any artefactual species. Several
studies have reported noncovalent protein–protein
interactions or dimers resistant to SDS, which result in
hydrophobic interactions [39–41]. Hydrophobic or
polar interactions between the hemopexin domains of
adjacent MT4-MMP molecules deserve more investiga-
tion to decipher their role in MT4-MMP dimerization.
The presence of noncovalent interactions in MT4-
MMP dimers is not surprising, as several reports have
described the importance of noncovalent interactions
in the oligomerization and dimerization of other
MMPs, including MMP2, MMP9, and MT1-MMP,
through their hemopexin domains [8,9,30]. In the case
of MT1-MMP, homophilic complex formation at the
cell surface requires the cooperation of two adjacent
MT1-MMP molecules to cleave proMMP2 or colla-
gen. A cysteine (Cys574) present in the cytosolic tail of
MT1-MMP has been reported to be involved in its
dimerization through the formation of an intermolecu-
lar disulfide bridge [28,42]. However, Itoh et al. have
proposed that the hemopexin-like domain of MT1-
MMP is responsible for homophilic complex formation
[29]. In contrast, Overall et al. failed to detect homod-
imers of MT1-MMP hemopexin domains [43]. More
recently, Lehti et al. concluded that both the hemo-
pexin-like and cytoplasmic domains of MT1-MMP are
involved in the formation of enzyme oligomers that
contribute to intermolecular proteolytic events at the
cell surface [30]. Subsequently, Seiki et al. have shown
that, in addition to the hemopexin domain, MT1-
MMP can form dimers through its transmembrane
domain [10].
Internalization kinetic assays revealed low levels of
MT4-MMP internalization after 15 min and higher
levels after 45–60 min. These kinetics are slower than
those of MT1-MMP, for which optimal internaliza-
tion is observed after 30 min [44]. This difference
in kinetics might be attributable to structural
differences between the molecules, related to their
membrane anchorage domains and probably to their
pericellular proteolytic performances. Similarly, inter-
nalization of the GPI-anchored MT6-MMP was
reported to be low as compared with that of MT1-
MMP [45]. MT1-MMP has a broader repertoire of
substrates than MT4-MMP, and the rapid internal-
ization of MT1-MMP probably contributes to the
control of its activity. Because of the poorer activity
of MT4-MMP [46], the pericellular functions of the
protein might require longer persistence at the cell
surface. Furthermore, GPI-anchored proteins are
known to accumulate and recycle slowly as com-
pared with proteins that use clathrin-dependent
endocytosis [47,48].
The inert MT4-E249A form was internalized at a
similar rate as MT4-WT, and was found intact in
cytosolic endosomes, whereas a fraction of the WT
form was subjected to autodegradation. The detection
of higher levels of intracellular MT4-WT upon treat-
ment with BB94 suggests autodegradation of the pro-
tein. Once internalized, MT4-MMP was found
associated with EEA1-positive endosomes. Interest-
ingly, some MT4-MMP was recycled intact to the cell
surface 30 min after its internalization. For the first
time, MT4-MMP bioavailability at the cell surface has
been found to be regulated through its internalization,
degradation and recycling in human breast cancer
cells. Through its recycling, MT4-MMP could be
repeatedly used by cancer cells during invasion and
metastatic dissemination.
MT1-MMP has been reported to colocalize with
caveolin-coated and clathrin-coated pits at the cell sur-
face, and to use both pathways for internalization [49].
We observed that MT4-MMP colocalized with cave-
olin but not with clathrin. This observation is in agree-
ment with a previous report showing that MT4-MMP
colocalizes with CAV-1 [38]. Intriguingly, MT4-MMP
internalization was not inhibited by either a caveolin
inhibitor or a clathrin inhibitor. We then hypothesized
that an alternative pathway may be used by MT4-
MMP for its internalization. Several studies have
reported that the CLIC/GEEC pathway plays a role in
the internalization of GPI-anchored proteins. Small
Rho GTPases involved in this pathway include
CDC42 and RhoA. By applying a siRNA approach,
we found that CDC42 and RhoA proteins are the
primary drivers of MT4-MMP internalization. In
contrast, silencing Rac1 only minimally affected
MT4-MMP internalization. CLIC/GEEC pathway-
dependent internalization was confirmed by two
approaches, including antibody feeding assays followed
by computerized quantification of confocal images and
FACS quantification, which showed 28% and 33%
increases in the level of cell surface MT4-MMP upon
CDC42 and RhoA silencing, respectively. Notably,
these values do not take into account a large amount
of MT4-MMP that may be shed from the cell surface
or autodegraded when internalization is inhibited by
the Rho GTPase siRNA. The latter was confirmed by
demonstrating that CDC42 silencing in MT4-E249A
cells led to its blockade at the cell surface, and that
this noninternalized inert form was found intact after
30 min of incubation at 37 °C, whereas the active
form was not stable under these conditions. These data
indicate that MT4-MMP internalization is efficiently
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inhibited by CDC42 siRNA, and that the resulting non-
internalized active form of MT4-MMP is autodegraded
and not available at the cell surface after 30 min.
Together, these data indicate that, in contrast to
MT1-MMP, which uses clathrin and caveolin as the
major endocytosis pathways, MT4-MMP endocytosis
is dependent on Rho GTPases and the CLIC/GEEC
pathway. The data presented here shed a new light on
the cellular and biochemical characteristics of MT4-
MMP, which is emerging as a prometastatic MT-
MMP with unique features among other MT-MMP
subfamilies.
MMPs exert their proteolytic activity and degrade
substantial barriers, facilitating angiogenesis, and
tumour growth, invasion, and metastasis [50,51]. How-
ever, MMPs show dual functions during cancer pro-
gression, based on their ability to: (a) degrade
extracellular matrix, which allows tissue invasion; and
(b) generate and/or release proangiogenic or anti-
angiogenic and inflammatory mediators [52]. This dual
function was pointed to as a key cause of clinical trial
failure with MMPIs [19,52]. Recently, it has emerged
that MMPs contribute to cancer progression and cell
signalling by non-proteolytic functions dependent on a
direct binding to adhesion molecules, integrins or tyro-
sine kinase receptors [1,2,53]. Thus, understanding
how the availability of MMPs at cell surface is regu-
lated is important, and promising for understanding
the failure of some targeted therapies.
Experimental procedures
Cell culture
Human breast cancer MDA-MB-231 cells and monkey
epithelial COS-1 cells were obtained from the American
Type Culture Collection (ATCC, Manassas, VA, USA). All
cell lines described above were authenticated before being
used in experiments. Cell line authentication for interspecies
contamination was performed by Leibniz-Institute DSMZ,
Braunschweig, Germany. Cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10% FBS, L-glutamine (2 mM), penicillin (100 UmL1)
and streptomycin (100 UmL1) at 37 °C in a 5% CO2
humid atmosphere. All culture reagents were purchased
from Gibco-Life Technologies (Invitrogen, Paisley, UK).
Transfection, plasmids, and mutagenesis
Plasmids carrying MT4-MMP were tagged by a FLAG
peptide (DYKDDDDK) after Pro319 or by a Myc peptide
(EQKLISEEDL) after Leu313 in the hinge region of the
protease (Fig. 1A). Stable transfectants were cultured in
medium containing 1.25 mgmL1 Geneticin (G418 sulfate;
Invitrogen Life Technologies, Grand Island, NY, USA).
For mutagenesis experiments, Cys564 and Cys566 in the
stem region of MT4-MMP were replaced with serines
(C564S and C566S, respectively) by use of the QuikChange
II XL Site-Directed Mutagenesis Kit (#200521, Agilent)
applied on WT pcMT4 cDNA (MT4-WT) and inactive
forms of pcMT4 cDNA (MT4-E249A) containing FLAG
or Myc tag (Fig. 1A). The generation of a stable MDA-
MB-231 cell line expressing MT4-MMP (MT4-WT) or
MT4-E249A was performed as previously described [32].
Coimmunoprecipitation assay
Coimmunoprecipitation assays were performed in COS-1
cells double-transfected with a FLAG-tagged human MT4
plasmid and a Myc-tagged human MT4 plasmid (see
above). Forty-eight hours after transient transfection, total
proteins were extracted with lysis buffer (50 mM Tris/HCl,
pH 7.4; 150 mM NaCl; 1% Nonidet P40; 1% Triton X-100;
1% sodium deoxycholate; 0.1% SDS) containing a Protease
Inhibitor Cocktail (complete; Roche). Protein lysates
(500 lg) were incubated with 2 lg of antibody against Myc
(M5546 or C3956; Sigma) and 50 lL of 50% slurry Dyn-
abeads protein G (Invitrogen) to coimmunoprecipitate
MT4-MMP and its protein partners. The precipitate was
subjected to western blotting with a mAb against FLAG
M2 (1 : 1000 dilution) (F3165; Sigma, St Louis, MO, USA)
and horseradish peroxidase-conjugated secondary antibody.
In some assays, COS-1 cells were incubated with the fol-
lowing MMPIs 24 h before protein extraction: GM-6001
(20 lM), BB94 (20 lM), or TIMP2 (100 ngmL1); DMSO
was used as a control.
RNA extraction and RT-PCR analysis
Total RNAs were extracted from cells at 70–80% confluence
with the High Pure RNA isolation kit (Roche Diagnostic
Applied Science, Mannheim, Germany). RT-PCR was
performed on 10 ng of total RNA extracted from MDA-
MB-231 cells with the GeneAmp Thermostable rTth Reverse
Transcriptase RNA PCR kit (Applied Biosystems, Foster
City, CA, USA), according to the manufacturer’s instruc-
tions. Specific primers for human MT4-MMP were designed
as follows: forward, 50-AAGGAGACAGGTACTGGG
TGTTC-30; and reverse, 50-TCGCCATCCAGCACTTTC
CAGTA-30 (Eurogentec, Seraing, Belgium). Thirty cycles of
amplification were run for 15 s at 94 °C, 20 s at 68 °C, and
30 s at 72 °C.
Western blotting
Cell protein extracts were prepared in lysis buffer (50 mM
Tris/HCl, pH 7.4; 150 mM NaCl; 1% Nonidet P40; 1% Tri-
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ton X-100; 1% sodium deoxycholate; 0.1% SDS) contain-
ing Protease Inhibitor Cocktail (complete; Roche). Proteins
were boiled for 5 min at 95 °C in loading buffer containing
2-mercaptoethanol before western blotting. In nonreducing
conditions, 2-mercaptoethanol was excluded from the load-
ing buffer. Protein samples were separated on 12% poly-
acrylamide gels, and transferred to poly(vinylidene
difluoride) membranes (NEN, Boston, MA, USA). Mem-
branes were blocked with 1% casein/0.1% Tween-20/PBS
(or 3% milk/0.1% Tween-20/PBS), and incubated over-
night with primary antibody at 4 °C, and then with a sec-
ondary horseradish peroxidase-conjugated anti-mouse Ig or
anti-rabbit IgG (Cell Signaling Technology, Danvers, MA,
USA). Signals were detected with an enhanced chemilumi-
nescence kit (Perkin-Elmer Life Sciences, Boston, MA,
USA). As a loading control, membranes were stripped and
reincubated with an antibody against actin (1 : 1000 dilu-
tion) (A2066; Sigma) or an antibody against HSC-70
(1 : 5000) (sc7298; Santa Cruz). The primary antibodies
used were: mAb against FLAG M2 (1 : 1000) (F3165;
Sigma, St Louis, MO, USA); antibodies against MT4-
MMP (MMP17) (1 : 1000) (ab39028 and ab51075; Abcam,
Cambridge, UK); antibody against CDC42 (0.5 lgmL1,
#610929; BD Transduction Laboratories, San Diego, CA,
USA); antibody against Rac1 (clone 23A8, 0.5 lgmL1,
#05-389; Millipore), or antibody against RhoA (26C4) (sc-
418, 0.8 lgmL1; Santa Cruz Biotechnologies, Santa Cruz,
CA, USA). Western blot density bands were quantified
with QUANTITY-ONE software (BioRad Laboratories, Her-
cules, CA, USA).
Cell surface biotinylation and recycling assay
Cells were grown in 10-cm-diameter or 15-cm-diameter
plates for MT4-MMP uptake and recycling assays, respec-
tively. This protocol was adapted from Remacle et al. [49].
Briefly, the cells were washed twice with cold PBS, and
once with Soerensen Buffer (SBS) (14.7 mM KH2PO4 and
2 mM Na2HPO4 with 120 mM sorbitol, pH 7.8), and incu-
bated for 10 min in SBS on ice. Biotinylation of cell surface
proteins was performed by adding 0.3 mgmL1 EZ-Link
Sulfo-NHS-SS-biotin (#21331; Thermo Scientific, Waltham,
MA, USA) in SBS for 20 min on ice. After several washes,
the excess biotin was quenched for 10 min on ice by incu-
bation in 100 mM glycine/SBS. After washing to remove
the glycine, the cells were incubated at 37 °C in serum-free
medium to allow the internalization of biotinylated plasma
membrane proteins. After various times (15, 30, 45 and
60 min) of incubation at 37 °C, the uptake was stopped by
washing the cells with ice-cold SBS and 10 min of incuba-
tion in SBS on ice. Biotin that remained present on cell sur-
face proteins was removed by a 25-min incubation with
150 mM MESNA, a membrane-impermeant reducing agent
(pH 8.2 in ice-cold SBS). After three washes with ice-cold
SBS, cell proteins were extracted with a lysis buffer (50 mM
Tris/HCl, pH 7.4; 150 mM NaCl; 1% Nonidet P40; 1% Tri-
ton X-100; 1% sodium deoxycholate; 0.1% SDS) contain-
ing Protease Inhibitor Cocktail (complete; Roche). In
some assays, the cells were incubated with BB94 for 24 h
before cell biotinylation. For the recycling assay, cells were
incubated for 45 min at 37 °C and treated with MESNA.
Next, the cells were incubated a second time at 37 °C for
30 min to allow recycling of the endocytosed biotinylated
proteins at the cell surface. Biotin re-exposed at the cell
surface was removed by a second MESNA treatment.
Finally, the cells were washed three times with ice-cold
SBS, and cell proteins were extracted with a lysis buffer as
described above. Biotinylated proteins (600–800 lg) were
pulled down with streptavidin–agarose beads (Sigma) over-
night at 4 °C, and used for the detection of MT4-MMP by
western blotting.
Immunofluorescence and confocal microscopy
MDA-MB-231 cells expressing MT4-WT or MT4-E249A were
grown on 12-mm sterile round glass coverslips. After 24 h of
incubation, the cells were washed with PBS and fixed for
15 min in 4% paraformaldehyde at room temperature. After
being washed, the cells were permeabilized for 5 min at room
temperature with 0.25% Triton X-100/PBS. The slides were
blocked in PBS containing 10% BSA solution, and incubated
with an antibody against FLAG (1 : 500 dilution, F1804;
Sigma, St Louis, MO, USA) in 3% BSA/PBS for 2 h at 37 °C.
The cells were then incubated with a secondary antibody, i.e.
Alexa Fluor 488 goat anti-(mouse IgG) (1 : 1000 dilution,
A11029; Invitrogen), in 3% BSA/PBS for 45 min at 37 °C,
and labelled with 40,6-diamidino-2-phenylindole dihydrochlo-
ride (D1306, 1 : 4000 dilution; Life Technologies) for 5 min at
room temperature to detect nuclei. Finally, the cells were
mounted on slides with Aqua-Poly/Mount CoverslippingMed-
ium (#18600; Polysciences). To block caveolin-dependent or
clathrin-dependent endocytosis, cells were incubated for 1 h in
serum-free medium with filipin III (5 lgmL1 and
10 lgmL1) or chlorpromazine (5 lgmL1), respectively.
For colocalization experiments, MDA-MB-231 cells expressing
MT4-MMP were stained with an antibody against FLAG (see
above) and an antibody against CAV-1 at 1 : 100 dilution
(C13630; Transduction Lab), or with an antibody against cla-
thrin heavy chain 1 (CHC-1) at 1 : 100 dilution (#2410; Cell
Signaling). The slides were analysed on an Olympus FV1000
confocal microscope with a 9 60 oil immersion objective
(Olympus America, Waltham, MA, USA).
Antibody feeding assay
Cells expressing MT4-WT-FLAG or MT4-E249A-FLAG
were grown on 12-mm glass coverslips for 24 h at 37 °C. The
cells were washed with PBS, and incubated at 37 °C for
30 min in serum-free DMEM supplemented with L-glutamine
(2 mM), penicillin (100 UmL1), streptomycin (100 UmL1),
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and 5% BSA Fraction V. The cells were then washed with
ice-cold DMEM and incubated for 15 min on ice. The
MDA-MB-231 cells were incubated with a mouse antibody
against FLAG M2 at 1 : 500 dilution (F1804; Sigma, St
Louis, MO, USA) for 1 h on ice. Unbound antibodies were
cleared by several washes. The cells were incubated for
different times at 37 °C to allow internalization of cell surface
MT4-MMP-FLAG marked by the antibody against FLAG.
The cells were finally fixed with 4% paraformaldehyde, per-
meabilized with 0.25% Triton X-100/PBS, and incubated with
a secondary antibody, i.e. Alexa Fluor 488-coupled goat anti-
mouse IgG (1 : 1000, A11029; Invitrogen), for 45 min at
37 °C. For experiments assessing colocalization of MT4-
MMP-FLAG and EEA1-positive early endosomes, the cells
were incubated for 1 h at 37 °C with an antibody against
EEA1 (ab2900; Abcam) and for 45 min at 37 °C with a
secondary antibody, i.e. Alexa Fluor 546 goat anti-(rabbit
IgG) (2 lgmL1, A11035; Invitrogen). For detection of
nuclei, the cells were incubated with 40,6-diamidino-2-pheny-
lindole dihydrochloride (1 : 4000, D1306; Life Technologies)
for 5 min at room temperature. In some assays, a red cell
membrane tracker, DY-554-phalloidin (554-33; Dyomics) was
used. Finally, the cells were mounted on slides with Aqua-
Poly/Mount Coverslipping Medium (#18600; Polysciences),
and confocal images were collected on an Olympus FV1000
microscope and analysed with Olympus FLUOVIEW (FV-10
ASW) software (Olympus America).
Computerized quantification of internalized and
cell surface MT4-MMP in immunofluorescence
experiments
Computerized image quantification was performed with the
image analysis toolbox of MATLAB R2014a (8.3.0.532)
(64-bit; MathWorks) applied on individual cells. Cell sur-
face staining and intracellular staining were automatically
detected, and the resulting images were binarized. Results
are expressed as the mean  standard error of the mean
(SEM) of the ratio between the intracellular staining areas
and the cell surface (internalized MT4-MMP density) or
total cell surface staining areas in a 2-lm-thick layer of cell
membrane marked with cell surface tracker in MT4-
E249A-expressing cells (cell surface MT4-E249A). For sta-
tistical analysis, Wilcoxon–Mann–Whitney tests were per-
formed. The levels of significance were: P > 0.05 [not
significant (NS)]; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; and
****P ≤ 0.0001.
siRNA transfection and flow cytometry
The expression levels of CDC42, Rac1 and RhoA were
downregulated by siRNA with calcium phosphate-
mediated transfection. The different siRNAs were incu-
bated in CaCl2 (2.5 M) before addition of Hepes-Buffered
Saline Phosphate (140 mM NaCl; 0.75 mM Na2HPO4;
6 mM glucose; 5 mM KCl; 25 mM Hepes, pH 7.05).
MT4-FLAG-expressing MDA-MB-231 cells and control
MDA-MB-231 cells were ultimately transfected with
20 nM siRNA. After 14–16 h of transfection, the cells
were washed and grown in six-well plates for 24 h. The
cells were then detached with Accutase, and incubated
with an FITC-conjugated mAb against FLAG M2 (clone
M2, F4049; Sigma) in 1% BSA/PBS for 60 min at 4 °C.
After washing, nonpermeabilized cells were analysed by
flow cytometry, with 10 000 events (FACSCalibur II; BD
Biosciences). The median fluorescence intensity for each
condition was normalized to control cells (MDA-MB-231
cells expressing empty pcDNA3-neo vector), and com-
pared with scrambled siRNA, which was considered to be
100%. The data represent two independent experiments.
The error bars correspond to the standard deviation.
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